MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
HYFT(NASDAQ:HYFT) AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk Holdings Corp.™ (“MindWalk™”, “Company”, “we” or “us”) (NASDAQ: HYFT), a Bio-Native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced financial results for its first fiscal quarter of 2026, ended July 31, 2025. All numbers are expressed in Canadian dollars unless otherwise noted. First Quarter Highlights: Record revenue of $7.6 million, up 45% year-over-year; continued operations revenue of $3.2 milli
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025
HYFT(NASDAQ:HYFT) AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #AI--MindWalk (NASDAQ: HYFT) (“HYFT” or the “Company”), a bio-native AI company operating at the intersection of TechBio and next-generation drug discovery, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year end 2026, on Monday, September 15, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. MindWalk management will ho
ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”
HYFT(HYFT) AUSTIN, Texas--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), ImmunoPrecise Antibodies Ltd. and its subsidiaries (BioStrand and Talem) today announced a unification under a single corporate brand, MindWalk, and a change of its Nasdaq ticker symbol to HYFT. The new identity conveys the Company’s evolution into a Bio-Native AI platform business built at the intersection of AI, multi-omics data, and advanced laboratory research. “Today is an evolutionary ste
